Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of$ 0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of$ 0.62 per share when it actually produced a loss of $0.89, delivering a surprise of -43 ...